Alison Liou

• Tessera Therapeutics in its global collaboration with Regeneron to jointly develop and commercialize TSRA-196, Tessera’s lead investigational in vivo gene writing program for the treatment of alpha-1 antitrypsin deficiency (AATD), with the companies sharing worldwide development costs and potential future profits relating to TSRA-196 equally, and Tessera receiving $150 million, inclusive of a cash upfront payment and equity investment, and development milestone payments totaling $125 million
• A hub-and-spoke biotherapeutics company in its strategic spin-out of a clinical-stage biopharma company leading development of hematologic and solid tumor therapeutics
• A venture-backed biotechnology company in its strategic research collaboration with Merck KGaA to discover novel RNA-targeting small molecules for neurological disorders
• A clinical-stage biotechnology company in its collaboration with a multinational, leading precision oncology company regarding the development and commercialization of cancer screening tests
• Apnimed in its acquisition of global rights to develop and commercialize sulthiame, a differentiated carbonic anhydrase inhibitor, from Desitin
• A venture-backed biotechnology company in its collaboration and license agreement with Genentech for the development of T cell-targeted therapies for an autoimmune disease
• Zealand Pharma in its collaboration with Roche on the largest ever single-asset partnership deal, worth up to $5.3 billion, to co-develop and co-commercialize petrelintide monotherapy and potential combination products, including petrelintide/CT-388, in the U.S. and Europe, as a therapy for people with obesity
• Tessera Therapeutics in its transaction with the Bill & Melinda Gates Foundation to jointly fund Tessera’s in vivo program for sickle cell disease, with potential total investment of up to $50 million from the Gates Foundation
• Tubulis in its exclusive option and license agreement with Gilead to discover and develop an antibody-drug conjugate against a solid tumor target, for an upfront payment of $20 million, an option exercise fee of $30 million, and up to $415 million in development and commercialization milestone payments, plus mid-single to low double-digit tiered royalties
• A venture-backed biotechnology company in its in-license of certain linker-payload technologies for the development and commercialization of next-generation antibody-drug conjugates
• Orum Therapeutics in its license and option agreement with Vertex to develop novel degrader-antibody conjugates, for an upfront payment of $15 million and up to $310 million per target in option and milestone payments for up to three targets, plus tiered royalties
• Kymera Therapeutics in its collaboration with NEOsphere Biotechnologies to discover novel molecular glue targets, for an upfront payment and success-based milestone payments
• Repertoire Immune Medicines in its strategic collaboration with Bristol Myers Squibb to develop tolerizing vaccines for up to three autoimmune diseases, for an upfront payment of $65 million and up to $1.8 billion in development, regulatory, and commercial milestone payments plus tiered royalties  
• An American multinational, pharmaceutical, and medical technologies corporation in its strategic spin-out of technology and intellectual property related to redirector antibodies and tumor target binding domains
• An American multinational, pharmaceutical, and medical technologies corporation in its strategic collaboration with Odyssey Therapeutics to advance AI-driven small molecule drug discovery
• Intellia Therapeutics in its expanded research collaboration with Regeneron Pharmaceuticals to develop additional in vivo CRISPR-based gene editing therapies focused on neurological and muscular diseases
• Aclipse Therapeutics in its exclusive, worldwide license agreement with Chong Kun Dang Pharmaceutical Corporation to develop potential disease-modifying treatments for gastroparesis
• Tubulis in its strategic license agreement with Bristol Myers Squibb to develop differentiated antibody-drug conjugates (ADCs) for cancer, for an upfront payment of $22.75 million and up to $1 billion in development, regulatory, and commercial milestone payments plus royalties
• Gladstone Institutes in connection with licensing and collaboration agreements
• Licensing of intellectual property assets from research institutions
• A public global biopharmaceutical company in its exclusive worldwide option and license agreement with a public immunotherapy company for a costimulation antagonist for autoimmune and inflammatory diseases*
• A public global biotechnology company in its strategic collaboration agreement with a public leading gene editing company to develop gene editing therapies for muscular dystrophies*
• A public global biotechnology company in its strategic collaboration agreement with a venture-backed biotechnology company to develop novel AAV capsids for genetic therapies*
• A public commercial-stage oncology company in its exclusive license agreement with a public Chinese pharmaceutical company to develop and commercialize its lead oncology compound in Greater China*
• A public biotechnology company in its strategic collaboration agreement with a venture-backed biopharmaceutical company to develop antibiotics for drug-resistant infections*
• A public biopharmaceutical company in its collaboration agreement with an antibody discovery company to develop antibody-based therapeutics*
• A leading university and a leading hospital in their research collaboration agreements with a healthcare investment firm to develop new therapies*
• A leading academic research institute in its collaboration and license agreements relating to its gene editing technologies*

* Denotes experience prior to joining Goodwin

• Royalty Pharma in its research and development co-funding agreement with J&J for a total of $500 million in 2026 and 2027 to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases
• Royalty Pharma in its $275 million royalty funding agreement with Denali Therapeutics
• R-Bridge Healthcare Fund, an affiliate of CBC Group, in its $38 million investment in royalties payable to Santhera Pharmaceuticals on sales of AGAMREE in North America and Greater China

• Tubulis in its acquisition by Gilead for $3.15 billion upfront and up to $1.85 billion in milestone payments
• AVROBIO in its combination with Tectonic Therapeutic in an all-stock transaction
• Prolaio in its acquisition of PhysIQ to enhance its cardiovascular care platform
• Alkermes in its completed separation of its oncology business into Mural Oncology
• Korro Bio on its merger with Frequency Therapeutics in an all-stock transaction
• Surface Oncology on its acquisition by Coherus in stock for stock transaction valued at up to $65 million plus contingent value rights

• Mercy BioAnalytics on its $41 million Series A financing and $59 million Series B financing

• Children’s Tumor Foundation in its collaborations to drive research, expand knowledge, and advance care for the neurofibromatosis community.
• ReNU Syndrome United in its collaborations to build a ReNU syndrome community, raise awareness about ReNU syndrome, and advance research on treatments for ReNU Syndrome.
• Shwachman-Diamond Syndrome (SDS) Alliance in its collaborations as a patient advocacy nonprofit to bring patients, caregivers, doctors, and researchers together to drive research and accelerate therapy development.